Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.08 +1.63%

+$0.10 today

Market cap
$114.01M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 1.24M

Average 0.66M

UPB Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Upstream Bio, Inc.NASDAQ: UPB

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of $985K rose 74.0% year over year, ahead of the +42.6% change in trailing-twelve-month gross profit. Sequentially, it rose 47.5% from the prior quarter. Over 3 fiscal years it compounded at +33.0% a year.

Context

  • Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +74.0% holds above the trailing-twelve-month pace of +42.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$985K+47.5% QoQ
Last fiscal yearDec 2025
$2.85M+20.4% YoY
LTMMar 2026
$3.27M+42.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+74.0%——
1 year+20.4%——
3-year CAGR+33.0%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
2.85M USD
Year-over-year change
+20.4%
3-year CAGR
+33.0%

Gross Profit vs competitors

How UPB compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +42.6% is the 6th highest of 10, against a peer median of +44.5%.
  • Gross profit amounts to 98.5% of revenue for UPB, versus a peer median of 95.9%.
UPB Competitors
Gross Profit for UPB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVAXNovavax, Inc.LTM Mar 2026$504.72M USD-54.0%+14.8%84.6%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$212.73M USD+396.6%—98.0%
WVEWave Life Sciences Ltd.LTM Mar 2026$67.34M USD-34.5%+110.2%93.8%
SYRESpyre Therapeutics, Inc.LTM Sep 2026$45.25M USD+200.0%—50.0%
UPBUpstream Bio, Inc.LTM Mar 2026$3.27M USD+42.6%+33.0%98.5%
PHVSPharvaris N.V.LTM Sep 2026-€106.45K EUR-9.7%——
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026-$108K USD+99.7%——
RLAYRelay Therapeutics, Inc.LTM Jun 2026-$58.64M USD+69.8%—566.6%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-$101.61M USD+44.5%+5.1%153.7%
ZBIOZenas BioPharma, Inc.LTM Mar 2026-$103.75M USD-98.2%——
Peer median (excluding UPB) —+44.5%+14.8%95.9%

Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.21M2.38M2.37M2.85M
Cost of Revenue0000
Gross Profit1.21M2.38M2.37M2.85M
Gross Margin100.0%100.0%100.0%100.0%
Research & Development18.66M31.8M62.97M136.81M
Selling, General & Admin6.46M10.7M17.17M26.41M
Operating Expenses25.12M42.49M80.13M163.22M
Depreciation & Amortization7K60K89K188K
EBITDA(23.86M)(20.48M)(62.72M)(143.26M)
EBITDA Margin-1968.7%-860.4%-2646.3%-5019.4%
Operating Income(23.91M)(40.11M)(77.76M)(160.36M)
Operating Margin-1972.7%-1685.5%-3281.2%-5618.8%
Interest Income205K4.17M12.12M16.93M
Interest Expense0000
Other Income / Expenses41K19.58M14.96M16.92M
Income Before Tax(23.87M)(20.54M)(62.81M)(143.44M)
Pre-Tax Margin-1969.3%-862.9%-2650.0%-5026.0%
Income Tax Expense0000
Net Income(23.87M)(20.54M)(62.81M)(143.44M)
Net Margin-1969.3%-862.9%-2650.0%-5026.0%
EPS (Basic)(0.66)(1.05)(1.49)(2.66)
EPS (Diluted)(0.66)(1.05)(1.49)(2.66)
Weighted Avg Shares36.32M36.32M51.34M53.85M
Weighted Avg Shares (Diluted)36.32M36.32M51.34M53.85M

Upstream Bio, Inc.

NASDAQ:UPB

Intrinsic Alpha fair value

Locked

Current Price

$2.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.